Adcetris
brentuximab vedotin · CD30Three xenograft models from human HL and ALCL cell lines
Zynlonta: animal efficacy model or human cells?
loncastuximab tesirine · CD19
Efficacy evidence
CD19-positive human Burkitt lymphoma (Ramos, Daudi) and DLBCL (WSU-DLCL2) xenografts in immunodeficient mice
“The in vivo activity of ADCT‐402 was evaluated in immunodeficient mice subcutaneously (SC) xenografted with the CD19 positive human Ramos or Daudi Burkitt’s lymphoma cell lines or with the CD19 positive human DLBCL cell line, WSU‐DLCL2 (Study No. ADCT‐402_R_007_R).”
Why that model
Antibody selective for human CD19; not cross-reactive with CD19 of any nonclinical species
“The monoclonal antibody (mAb) component of loncastuximab tesirine, RB4v1.2, is selective for human CD19 and not cross‐reactive with CD19 from any nonclinical species.”
Reviewer's view of the efficacy data
EMA: studies in lymphoma/leukaemia patient-derived cell lines supported clinical testing; cancer cell lines accepted for ADCs
“The nonclinical studies conducted with ADCT-402 using a panel of cell lines derived from lymphoma and leukaemia patients have supported the clinical testing of loncastuximab tesirine in patients. Findings from these nonclinical studies support the use of cancer cell lines for nonclinical studies with ADCs.”
Same question, other ADCs
Besponsa
inotuzumab ozogamicin · CD22Subcutaneous xenograft and systemically disseminated ALL mouse models
Datroway
datopotamab deruxtecan · Trop-2Nude mouse xenografts of human pancreatic cancer, NSCLC and breast cancer
Decnupaz
pivekimab sunirine · CD123Two BPDCN patient-derived xenograft (PDX) models in NSG mice
Elahere
mirvetuximab soravtansine · FRαOvarian cancer xenograft mouse models (single IV dose)
Emrelis
telisotuzumab vedotin · c-Metc-Met-positive NSCLC cell line-derived and patient-derived xenograft mouse models
Enhertu
fam-trastuzumab deruxtecan · HER2HER2-positive breast cancer xenograft mouse models (e.g., KPL-4 in nude mice)
Kadcyla
ado-trastuzumab emtansine · HER2HER2+ xenografts (BT-474 EI, Calu-3) and MMTV-HER2 transgenic tumor model; growth inhibition in all three at 3 to 31 mg/kg
Mylotarg
gemtuzumab ozogamicin · CD33CD33+ HL-60 leukemia xenograft in mice: >80% tumor growth inhibition
Padcev
enfortumab vedotin · Nectin-4Nectin-4-expressing patient-derived bladder cancer xenografts (AG-B1, AG-B8) in mice: >75% tumor growth inhibition
Polivy
polatuzumab vedotin · CD79bHuman DLBCL and B-cell lymphoma xenografts in mice; in vitro Ramos cytotoxicity
Tivdak
tisotumab vedotin · Tissue factorCervical cancer patient-derived xenograft (PDX) models in mice
Trodelvy
sacituzumab govitecan · Trop-2Mouse xenografts bearing human Trop-2-expressing tumours